RxDoctor Payments Data

Jose Rodriguez Escudero, MD

Cardiovascular Disease · San Juan, PRNPI 1639169204

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,218 of the $10,691 with a category attached, or 76.9%. It is spread thinly across 19 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.

$10,691in general payments, 2019–2025

Across 163 payments — averaging $65.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Impulse Dynamics (USA) Inc.$2K
  • Abbott$2K
  • E.r. Squibb & Sons, L.L.C.$926
  • AstraZeneca$757
  • Amgen$709
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$1,17011%
  • Travel & lodging$1,28112%
  • Food & beverage$8,21877%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson21$2,095
Impulse Dynamics (USA) Inc.6$1,637
Abbott28$1,566
E.r. Squibb & Sons, L.L.C.13$926
AstraZeneca20$757
Amgen12$709
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)13$669
Boehringer Ingelheim14$587
Medtronic4$371
Bayer2$238
Boston Scientific3$209
Eli Lilly Export S.A. Puerto Rico Branch2$200
Bayer Puerto Rico Inc.8$153
PBG Puerto Rico LLC8$147
Lilly USA, LLC1$119
Pfizer Pharmaceuticals LLC2$118
Pfizer2$92
Novartis3$80
Scpharmaceuticals Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,691 in reported general payments places this provider in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$109,093
Medicare patients
310
Services billed
1,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban225$229,687
XareltoRivaroxaban127$124,312
BrilintaTicagrelor96$62,076
JardianceEmpagliflozin52$46,503
SynthroidLevothyroxine Sodium451$42,708
FarxigaDapagliflozin Propanediol44$38,312
JanumetSitagliptin Phos/Metformin Hcl21$28,018
Repatha SureclickEvolocumab47$26,461
Metoprolol Succinate999$19,147
Candesartan Cilexetil137$15,493
Valsartan360$14,575
Trijardy XrEmpaglifloz/Linaglip/Metformin11$14,037
MultaqDronedarone Hcl17$13,987
Irbesartan413$13,162
EntrestoSacubitril/Valsartan14$12,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$92$229,687225 claims
Johnson & JohnsonXarelto$2,095$124,312127 claims
AstraZenecaBrilinta, Farxiga$757$100,388140 claims
Boehringer IngelheimJardiance, Trijardy Xr$587$60,53963 claims
NovartisEntresto$80$12,39114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →